---
title: "Jinling Pharmaceutical Company Limited (000919.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/000919.SZ.md"
symbol: "000919.SZ"
name: "Jinling Pharmaceutical Company Limited"
industry: "Pharmaceuticals"
---

# Jinling Pharmaceutical Company Limited (000919.SZ)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | CN Market |
| Website | [www.jlyy1999.com](https://www.jlyy1999.com) |

## Company Profile

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arterios...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-02T04:30:11.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 149 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.52% |  |
| Net Profit YoY | -62.37% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.24 |  |
| Dividend Ratio | 1.33% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.71B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.14B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.85% | D |
| Profit Margin | 1.03% | C |
| Gross Margin | 23.15% | D |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.52% | E |
| Net Profit YoY | -62.37% | D |
| Total Assets YoY | 12.48% | B |
| Net Assets YoY | 9.23% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 9750.34% | A |
| OCF YoY | -13.52% | E |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.55 | C |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 19.54% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Jinling Pharmaceutical Company Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.85%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "1.03%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "23.15%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-13.52%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-62.37%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "12.48%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.23%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "9750.34%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-13.52%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "19.54%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A |
| 02 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B |
| 03 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B |
| 04 | Salubris (SZ.002294) | B | B | C | A | B | B |
| 05 | Haisco (SZ.002653) | B | C | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 142.74 | 143/222 | 233.20 | 145.26 | 131.51 |
| PB | 1.21 | 12/222 | 1.22 | 1.16 | 1.11 |
| PS (TTM) | 1.46 | 16/222 | 1.48 | 1.40 | 1.31 |
| Dividend Yield | 1.36% | 90/222 | 1.49% | 1.40% | 1.35% |

## References

- [Company Overview](https://longbridge.com/en/quote/000919.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/000919.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/000919.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.